Business Wire

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Jaa

Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia.

“By joining forces with Vanderbilt University, one of the world’s leading groups integrating basic neuroscience and new translational approaches in neuropsychiatric conditions, Boehringer Ingelheim will strengthen and expand efforts to bring new treatments to patients,” said Bernd Sommer, Ph.D., Global Head CNS Disease Research, Boehringer Ingelheim. “Our colleagues in VCNDD share our strategic vision for drug discovery to regulate maladaptive brain circuitry as the key to alleviate symptoms in neuropsychiatric conditions and bring relief to patients suffering from these debilitating disorders.”

Maladaptive brain circuits are the neurobiological basis of major symptoms in many mental disorders. These symptoms may include memory, concentration and decision-making difficulties as well as social withdrawal, lack of motivation or inability to experience pleasure. Because GPCRs have specific roles in the regulation and modulation of brain circuit functions, these proteins are promising targets for drugs designed to relieve such symptoms. VCNDD has pioneered GPCRs research, yielding a better understanding of their roles in brain modulation.

“We are delighted to partner with Boehringer Ingelheim in developing new treatments for schizophrenia and other major psychiatric disorders,” said P. Jeffrey Conn, VCNDD director. “Boehringer Ingelheim is an industry leader that shares our passion for advancing new therapeutic strategies that could dramatically improve the standard of care for individuals suffering from major mental illness. Through this partnership, we are able to pursue new approaches for correcting deficits in brain circuits that may allow treatment of debilitating symptoms that are not responsive to available medicines.”

Craig W. Lindsley, VCNDD’s director of medicinal chemistry, echoed enthusiasm for the partnership. “The programs partnered with Boehringer Ingelheim represent the culmination of years of basic and translational science within our center and highlight the key role academic drug discovery centers can have on the future of human mental health,” he said.

These new industry-academic collaborations may be the first to focus on the two GPCR targets with a goal to address the unmet medical needs for treatments of cognitive and negative symptoms associated with schizophrenia. The partnership also will enhance the educational goals of VCNDD to train doctoral students and post-doctoral fellows and develop new tools to advance neuroscience knowledge. Further details of the agreement are not disclosed. The present agreements to identify novel therapies for the treatment of neurological conditions are the fifth and sixth agreements between Boehringer Ingelheim and Vanderbilt University, adding to previous agreements focused on the identification of novel therapies for cancer.

About Neuropsychiatric Disorders

Brain or neurological conditions that cause psychiatric symptoms are referred to as neuropsychiatric disorders. The World Health Organization (WHO) reports that neuropsychiatric disorders are the third leading cause of years lived with disability (DALY).1 Moreover, these disorders include mental and behavioral conditions such as depression, anxiety, drug- and alcohol-use disorders, schizophrenia, bipolar disorder and other illnesses2 that together account for 7.4 percent of total global DALYs.3

Please click on the link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/collaboration-vanderbilt-university

Contact information

Media:
Boehringer Ingelheim
Linda Ruckel
Linda.ruckel@boehringer-ingelheim.com
917-692-0848

Vanderbilt University
Heidi Hall
Heidi.Hall@Vanderbilt.edu
615-689-8419

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Mass Deployments of IoT Solutions Transforming China, Says GSMA27.6.2019 04:30:00 EESTTiedote

Chinese mobile operators are leading the world in the deployment of transformative Internet of Things (IoT) solutions, the GSMA announced today. By connecting the estimated 960 million1 devices via cellular networks, the country is realising the value of the IoT and transforming society through mass market deployments of smart home, smart industry and smart city solutions. According to GSMA Intelligence, China is the world’s largest IoT market with 64 per cent of the 1.5 billion global cellular connections including the rapidly growing Mobile IoT licensed LPWA technologies2. “Backed by proactive government support, China is now at the forefront in the development and mass deployment of innovative and transformative IoT based solutions based on Mobile IoT technology,” said Alex Sinclair, Chief Technology Officer, GSMA. “These new technologies are being implemented across multiple different vertical sectors fundamentally altering the way we live and work, delivering real-time information

Gemalto Instant Connect Signals New Era in Effortless Mobile Connectivity for Consumer eSIM-equipped Devices  27.6.2019 02:00:00 EESTTiedote

Thales announces the launch of Gemalto Instant Connect, a pioneering connectivity solution to simplify the connection of eSIM-enabled devices on a mobile network. While users are spared the inconvenience of establishing a Wi-Fi or Bluetooth connection to kick-start their mobile experience, OEMs and mobile operators can now provision devices with mobile connectivity at their first use, and not during manufacturing, saving both time and cost. Connected PCs and laptops will be the first devices to integrate this faster and more efficient approach to out-of-the-box connectivity for eSIMs. Going forwards, a wide array of OEMs and mobile operators stand to benefit from the solution, which is fully compliant with the latest GSMA Remote SIM Provisioning specifications. Between 2018 and 2022, an estimated 2.3 billion eSIM-compliant consumer devices will be shipped worldwide 1 . To date, eSIM-equipped devices have had to rely on some form of primary connectivity before they are able to activate

Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier26.6.2019 23:00:00 EESTTiedote

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications. Uman, based in Umeå, Sweden, supplies Nf-L antibodies and ELISA kits, which are widely recognized by researchers and biopharmaceutical and diagnostics companies world-wide as the premier solution for the detection of Nf-L to advance the development of therapeutics and diagnostics for neurodegenerative conditions. Nf-L has seen a dramatic growth in the last three years since Quanterix developed the first assay using Uman’s antibodies that could relia

Elliott Statement on Bayer26.6.2019 19:44:00 EESTTiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds that collectively hold shares of Bayer A.G. (“Bayer” or “the Company”) and economic equivalents with an aggregate value of €1.1 billion, acknowledges Bayer’s announcement to create a special litigation committee of the Supervisory Board (the “Special Committee”), and the retention of Mr. John Beisner of Skadden, Arps, Slate, Meagher & Flom LLP, as legal advisor to the Supervisory Board and Special Committee. Elliott welcomes these steps, and is confident that today’s statement marks a step change in Bayer’s approach to addressing the legal challenges currently facing the Company. Elliott believes that the creation of the Special Committee will provide a new level of oversight and a fresh perspective to a litigation strategy in need of a radical overhaul, and help guide the Company towards a rational, fair and swift settlement. The appointment of Mr. John Beisner not only provides Bayer with relevant litigation expertise, bu

Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease26.6.2019 18:30:00 EESTTiedote

Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), to announce a deal that will allow the implementation of an innovative payment model for hepatitis C treatment, part of Louisiana’s plan to eliminate the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005539/en/ “This new model has the potential to save many lives and improve the health of our citizens. It is an important day for our state, for our partner Asegua Therapeutics, for providers, but most importantly for the patients and their families who will benefit from treatment,” said Governor Edwards. “Asegua was willing to come to the table to work with us to help Louisiana residents and we are pleased to initiate this five year partnership. Ultim

Nextflow Software Introduces Nextflow Studio, Its Newest Fluid Simulation Software26.6.2019 17:00:00 EESTTiedote

Nextflow Software is an Independent Software Vendor (ISV) based in Nantes, France. Nextflow Software is one of the leaders in innovative Computational Fluid Dynamics (CFD) methods. The startup exhibits at the NAFEMS World Congress in Quebec City, Canada, on June 17-20, featuring live demos if its latest product Nextflow Studio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005482/en/ Nextflow Studio conception simulation (Photo: Nextflow Software) A full environment covering all stages of CFD simulation Nextflow Studio is a software platform that covers the entire CFD flow, from pre-processing, to computation and post-processing. This environment lets engineers manage easily their simulation projects and provides a Graphical User Interface (GUI) based on the latest software technologies. Nextflow Studio offers an experience that allows users to accelerate the resolution of their field-specific design objectives. Main

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme